Gleason score predicts androgen independent progression after androgen deprivation therapy.
暂无分享,去创建一个
[1] R. Sylvester,et al. Prostatic Specific Antigen and the Prediction of Prognosis in Metastatic Prostatic Cancer , 1990, Cancer.
[2] A W Partin,et al. Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of followup. , 1993, The Journal of urology.
[3] N. Vogelzang,et al. Independent Prognostic Factors in Patients With Metastatic (Stage D2) Prostate Cancer , 1991 .
[4] I. Thompson,et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. , 1998, The New England journal of medicine.
[5] J. Hanley,et al. Competing Risk Analysis of Men Aged 55 to 74 Years at Diagnosis Managed Conservatively for Clinically Localized Prostate Cancer , 1998 .
[6] P. Goodman,et al. Leuprolide With and Without Flutamide in Advanced Prostate Cancer , 1990, Cancer.
[7] A W Partin,et al. Natural history of progression after PSA elevation following radical prostatectomy. , 1999, JAMA.
[8] A. Renshaw,et al. Biochemical Outcome after radical prostatectomy, external beam Radiation Therapy, or interstitial Radiation therapy for clinically localized prostate cancer , 1998 .
[9] Mc,et al. Treatment Options for Prostate Cancer: Part 1--Stage, Grade, PSA, and Changes in the 1990's , 1998 .
[10] J. Miller,et al. The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer. , 1992, The Journal of urology.
[11] Z. Braf,et al. Changes in prostate‐specific markers under chronic gonadotrophin‐releasing hormone analogue treatment of stage D prostatic cancer , 1989, Cancer.
[12] E. Crawford,et al. Prognostic factors in stage D2 prostate cancer; important implications for future trials: results of a cooperative intergroup study (INT.0036). The National Cancer Institute Intergroup Study #0036. , 1994, Seminars in oncology.
[13] T. Stamey,et al. Biological determinants of cancer progression in men with prostate cancer. , 1999, JAMA.
[14] N. Vogelzang,et al. Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. The Zoladex Study Group. , 1991, JAMA.
[15] G. Chodak. The role of watchful waiting in the management of localized prostate cancer. , 1994, The Journal of urology.
[16] P. Goodman,et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. , 1989, The New England journal of medicine.
[17] A W Partin,et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. , 1997, JAMA.
[18] R. Sylvester,et al. The Importance of Prognostic Factors in the Interpretation of Two EORTC Metastatic Prostate Cancer Trials , 1998, European Urology.
[19] R. Sylvester,et al. Maximal Androgen Blockade: Final Analysis of EORTC Phase III Trial 30853 , 1998, European Urology.